Postoperative multidrug-resistant Acinetobacter baumannii meningitis successfully treated with intravenous doxycycline and intraventricular gentamicin: A case report

Xia Wu, Lu Wang, Ying-Zi Ye, Hui Yu

Abstract

BACKGROUND
Multidrug-resistant Acinetobacter baumannii (MDRAB) has emerged as an increasingly important pathogen that causes nosocomial meningitis. However, MDRAB-associated nosocomial meningitis is rarely reported in children.

CASE SUMMARY
We report the case of a 1-year-old girl with a choroid plexus papilloma, who developed postoperative nosocomial meningitis due to MDRAB. The bacterial strain was sensitive only to tigecycline and colistin, and showed varying degrees of resistance to penicillin, amikacin, ceftriaxone, cefixime, cefotaxime, ciprofloxacin, levofloxacin, gentamicin, meropenem, imipenem, and tobramycin. She was cured with intravenous doxycycline and intraventricular gentamicin treatment.

CONCLUSION
Doxycycline and gentamicin were shown to be effective and safe in the treatment of a pediatric case of MDRAB meningitis.

Key words: Acinetobacter baumannii; Meningitis; Doxycycline; Gentamicin; Multidrug resistance; Case report

©The Author(s) 2019. Published by Baishideng Publishing Group Inc. All rights reserved.

Core tip: Multidrug-resistant Acinetobacter baumannii (MDRAB) is a troublesome pathogen owing to multidrug resistance. Postoperative nosocomial meningitis due to
Acinetobacter baumannii is rarely reported in children. Nosocomial meningitis due to MDRAB is fatal and its treatment is challenging because of the low blood-brain barrier permeability of antibiotic drugs. We describe the case of a child who developed post-neurosurgical meningitis due to MDRAB that was effectively treated by the combination of intravenous doxycycline and intraventricular gentamicin administration.

**INTRODUCTION**

Acinetobacter baumannii (A. baumannii) is a Gram-negative bacterium that causes various nosocomial infections\(^1\)\(^-\)\(^2\). Postoperative nosocomial meningitis due to A. baumannii is rarely reported in children. Treatment of A. baumannii infection is of concern due to the increasing prevalence of multidrug resistance\(^3\). In this report, we present the case of a child who developed post-neurosurgical meningitis due to multidrug-resistant A. baumannii (MDRAB). The child was successfully treated with intravenous doxycycline and intraventricular gentamicin administration. This report also presents a systematic literature review concerning MDRAB-associated nosocomial meningitis in children.

**CASE PRESENTATION**

**Chief complaints**

A 1-year-old girl with head trauma was admitted to our hospital in November 2016. At four weeks after surgery, the patient was febrile and disturbance of consciousness was observed.

**History of present illness**

The patient fell off the bed and mild head trauma was suspected. Incidentally, a computed tomography (CT) scan of the head revealed an intracranial space-occupying lesion (Figure 1A). One week after the admission, the child underwent a brain tumor resection. Immunohistochemical staining of the specimens indicated a choroid plexus papilloma. On the fourth postoperative week, she suddenly developed an altered state of consciousness with febrile illness. External ventricular drainage was performed. During the course of the disease, the patient had no diarrhea, abdominal pain, nausea, vomiting, cold, or any other discomfort.

**History of past illness**

The patient had no medical history of chronic diseases such as diabetes, coronary and other heart diseases, infectious diseases such as hepatitis and tuberculosis, surgery, blood transfusion, trauma, and drug allergy. The patient’s history of preventive inoculation was unknown.

**Personal and family history**

She was operated for a choroid plexus papilloma in November 2016. The rest of the personal and family history was unexceptional.

**Physical examination upon admission**

At admission, the patient showed stable vital signs; however, the skin on the right side of the forehead was swollen, approximately 5.5 cm × 4 cm in size. On the fourth postoperative week, she suddenly developed an altered state of consciousness and hypertonia of limbs, along with the disappearance of the direct and indirect pupillary light reflexes.

**Laboratory examinations**

Cerebrospinal fluid (CSF) examination showed a white blood cell count of 500/mm\(^3\). The patient was diagnosed with meningitis and intravenous administrations of...
Figure 1  Computed tomography images. A: Computed tomography (CT) showed an intracranial space-occupying lesion; B-G: CT examination results during patient follow-up.

meropenem (120 mg/kg/d divided q8h) and vancomycin (60 mg/kg/d divided q6h) were initiated; however, the patient did not show any improvement. After 5 d, CSF analysis showed a white blood cell count of 40000/mm$^3$, protein concentration of 573 mg/dL, and glucose concentration of 0 mmol/L. CSF culture was positive for *A. baumannii*, which was sensitive only to tigecycline and colistin while it showed varying degrees of resistance to penicillin, amikacin, ceftriaxone, cefixime, cefotaxime, ciprofloxacin, levofloxacin, gentamicin, meropenem, imipenem, and tobramycin.

**FINAL DIAGNOSIS**

Postoperative MDRAB meningitis.

**TREATMENT**

As colistin has severe side effects in children, the patient was started on tigecycline (2 mg/kg/d divided q12h). After 12 d of antibiotic therapy with tigecycline, the patient still had a fever. The CSF culture was positive for MDRAB. Doxycycline is known to be active against MDRAB and was administered to the patient following the failure of tigecycline (4 mg/kg/d divided q12h) and intraventricular gentamicin (2 mg/d, once daily) was administered. The patient became afebrile 6 d later. After 17 d, the CSF was found to be sterile. Doxycycline and gentamicin were administered for 8 wk. The clinical course of the patient is shown in Figure 2.
OUTCOME AND FOLLOW-UP

There were no serious side effects of doxycycline and gentamicin treatment. The patient is now healthy and is receiving scheduled follow-up and her CT examination results remained normal at the subsequent two-year follow-up (Figure 1).

DISCUSSION

MDRAB is a troublesome pathogen in healthcare institutions owing to multidrug resistance, which is a threat to the current antibiotic era\(^5\). Nosocomial meningitis due to MDRAB is fatal and its treatment is challenging because of the low blood-brain barrier permeability of antibiotic drugs\(^5\). Thus, the choice of antibiotics is critical to the treatment of nosocomial MDRAB meningitis. It is also important to analyze the blood and CSF cultures before treatment initiation to avoid inappropriate antibiotic use. In the present case, CSF culture showed the presence of MDRAB that was sensitive only to tigecycline and colistin.

In the past, colistin had been used successfully against Gram-negative bacteria; however, its prescription decreased due to nephrotoxicity\(^7\). Tigecycline is a broad-spectrum bacteriostatic compound of glycylcyclines, which is active against several multidrug-resistant pathogens as well as MDRAB\(^8\). In our case, tigecycline was initially administered intravenously, but the patient did not respond to the treatment and continued to manifest typical signs of meningitis. The possible explanation of the therapeutic failure of intravenous tigecycline treatment could be attributed to its poor ability to penetrate through the blood-brain barrier. Thus, a combination of intravenous and intraventricular (IVT) antibiotic administration may be a therapeutic option to ensure sterilization of the CSF. Both doxycycline and tigecycline belong to the tetracycline class of antibiotics. Doxycycline was administered following the failure of tigecycline, known to be active against MDRAB. In our case, doxycycline was effective in the treatment of the CNS infection, which may be explained by an...
increased doxycycline distribution in the CNS owing to the disruption of the blood-brain barrier, in inflammatory diseases like meningitis. However, further pharmacological studies are needed to confirm this observation. Moreover, the intraventricular gentamicin administration could effectively sterilize the CSF.

MDRAB has emerged as an increasingly important pathogen often associated with post-neurosurgical meningitis[9]. In the literature, the number of pediatric cases with MDRAB meningitis is low. Data regarding the clinical characteristics, therapy, and treatment outcomes in pediatric cases are summarized in Table 1[10-13]. Since active antibiotics including tigecycline and colistin diffuse poorly to the central nervous system, it is a challenge to treat patients via intravenous administration of these drugs. The IVT administration of these antibiotics is currently the only treatment option for MDRAB meningitis.

CONCLUSION

In conclusion, this case suggests that the combination of intravenous doxycycline and intraventricular gentamicin administration may be a potentially effective and safe therapeutic option for the treatment of childhood MDRAB meningitis.
### Table 1  Clinical features of the reported series of multidrug-resistant Acinetobacter baumannii meningitis in children

| Ref. | Age (yr) | Sex | Acinetobacter susceptibility | Final regimen(s) | Toxicity | Treatment outcome |
|------|----------|-----|-------------------------------|-------------------|----------|------------------|
| Kaplan et al\[^{[10]}\] | 4 | NR | Multidrug resistant | Cefotaxime and aminoglycoside IV, and colistin IVR | None | Cure |
| Ng et al\[^{[11]}\] | 4 | Male | Multidrug resistant | Amikacin and colistin IV, and colistin IT | Chemical meningitis | Cure |
| Ozdemir et al\[^{[13]}\] | 3 | Female | Colistin | Colistin and ampicillin-sulbactam IV, and colistin IT | None | Cure |
| | 14 | Female | Colistin | Meropenem and ampicillin-sulbactam IV, and rifampin PO | None | Cure |
| Lee et al\[^{[12]}\] | 1 | Male | Colistin | Colistin and meropenem IV | None | Cure |
| Ganjeifar et al\[^{[14]}\] | 3 | Male | Imipenem | Colistin IV | None | Cure |
| | 6 | Male | Doxycycline and rifampin | Colistin and rifampin IV, and colistin IVR | NR | Cure |
| Jiménez-Mejías et al\[^{[15]}\] | 14 | Male | Colistin | Colistin IV | None | Cure |

IT: Intrathecal; IV: Intravenous; IVR: Intraventricular; PO: Peroral; NR: Not reported.

---

**REFERENCES**

1. Munoz-Price LS, Weinstein RA. Acinetobacter infection. *N Engl J Med* 2008; 358: 1271-1281 [PMID: 18354105 DOI: 10.1056/NEJMra070741]
2. Bergogne-Bérézin E, Towner KJ. Acinetobacter spp. as nosocomial pathogens: microbiological, clinical, and epidemiological features. *Clin Microbiol Rev* 1996; 9: 148-165 [PMID: 8964033 DOI: 10.1128/CMR.9.2.148]
3. Peleg AY, Seifert H, Paterson DL. Acinetobacter baumannii: emergence of a successful pathogen. *Clin Microbiol Rev* 2008; 21: 538-582 [PMID: 18625687 DOI: 10.1128/CMR.00058-07]
4. Kim BN. Peleg AY, Lodise TP, Lipman J, Li J, Nation R, Paterson DL. Management of meningitis due to antibiotic-resistant Acinetobacter species. *Lancet Infect Dis* 2009; 9: 245-255 [PMID: 19324297 DOI: 10.1016/S1473-3099(09)70555-6]
5. Jain R, Danziger LH. Multidrug-resistant Acinetobacter infections: an emerging challenge to clinicians. *Ann Pharmacother* 2004; 38: 1449-1459 [PMID: 15280512 DOI: 10.1345/aph.1D352]
6. Levin AS, Barone AA, Penço J, Santos MV, Marinho IS, Arruda EA, Manrique EI, Costa SF. Intraventricular colistin as therapy for nosocomial infections caused by multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii. *Clin Infect Dis* 1999; 28: 1008-1011 [PMID: 10452626 DOI: 10.1086/514732]
7. Karageorgopoulos DE, Falugas ME. Current control and treatment of multidrug-resistant Acinetobacter baumannii infections. *Lancet Infect Dis* 2008; 8: 751-762 [PMID: 19022191 DOI: 10.1016/S1473-3099(08)70279-2]
8. Pankey GA. Tigecycline. *J Antimicrob Chemother* 2005; 56: 470-480 [PMID: 16040625 DOI: 10.1093/jac/dk248]
9. Giamarellou H, Antoniadou A, Kanellakopoulou K. Acinetobacter baumannii: a universal threat to public health? *Int J Antimicrob Agents* 2008; 32: 106-119 [PMID: 18571905 DOI: 10.1016/j.ijantimicag.2008.02.013]
10. Kaplan SL, Patrick CC. Cefotaxime and aminoglycoside treatment of meningitis caused by gram-negative enteric organisms. *Pediatr Infect Dis J* 1990; 9: 810-814 [PMID: 2263430 DOI: 10.1097/00006454-199011000-00006]
11. Ng J, Goshell IB, Kelly JA, Boyle MJ, Ferguson JK. Cure of multiresistant Acinetobacter baumannii central nervous system infections with intraventricular or intrathecal colistin: case series and literature review. *J Antimicrob Chemother* 2006; 58: 1078-1081 [PMID: 16918866 DOI: 10.1093/jac/dkl347]
12. Ozdemir H, Tapsiz A, Çiçci E, Ince E, Mokhtari H, Güriz H, Aysev AD, Doğru U. Successful treatment of three children with post-neurosurgical multidrug-resistant Acinetobacter baumannii meningitis. *Infection* 2016; 38: 241-244 [PMID: 20358244 DOI: 10.1007/s11550-010-0018-z]
13. Lee SY, Lee JW, Jeong DC, Chung SY, Chung DS, Kang JH. Multidrug-resistant Acinetobacter baumannii meningitis in a 3-year-old boy treated with i.v. colistin. *Pediatr Int* 2008; 50: 584-585 [PMID: 18937759 DOI: 10.1111/j.1442-200X.2008.02067.x]
14. Ganjeifar B, Zabihyan S, Baharvahdat H, Baradaran A. Multidrug-resistant Acinetobacter baumannii ventriculitis: a serious clinical challenge for neurosurgeons. *Br J Neurosurg* 2016; 30: 589-590 [PMID: 27387018 DOI: 10.1080/02688697.2016.1206133]
15. Jiménez-Mejías ME, Pichardo-Guerrero C, Martínez-Rivas FF, Martín-Lozano D, Prados T, Pachón J. Cerebrospinal fluid penetration and pharmacokinetic/pharmacodynamic parameters of intravenously administered colistin in a case of multidrug-resistant Acinetobacter baumannii meningitis. *Eur J Clin Infect Dis* 2008; 4(1): 24-28 [PMID: 18869648 DOI: 10.1111/j.1465-1337.2007.02027.x]

**Treatment of postoperative MDRAB meningitis** by Wu X et al.
